Dani Bancroft, Author at Labiotech.eu

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

biotech infographic personalised edicine genetic disease

News and Trends 15 Jul 2016

Infographic: What are the key challenges in Personalized Medicine?

Personalized medicine is the way forward in tackling hard-to-treat indications. Here are some of the challenges in R&D of such therapies in biotech. By exploring use of autologous therapies, the chance of adverse responses from immunogenicity is reduced, making the treatment more targeted and effective (as doses can be higher). However, there are challenges in […]

July 15, 2016 - 1 minutemin - By Dani Bancroft

News and Trends 14 Jul 2016

Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

Themis is a Vienna-based vaccine developer. Together with the Institut Pasteur, it is now planning to use a measles vaccine construct to develop and start Zika vaccine trials within the next 12 months. Themis has successfully extended its existing license agreement with Institut Pasteur in Paris, which grants the company a broad access to a well-established virus vaccine vector technology. The […]

July 14, 2016 - 3 minutesmins - By Dani Bancroft

oxitec brazil mosquito gmo vector control zika dengue malaria city

News and Trends 14 Jul 2016

UPDATE: Brazilian city to be first in World to deploy GM Mosquitos against Dengue Fever

Oxitec‘s genetically engineered Mosquito trial is being expanded in Brazil’s Piracicaba region, to cover a city of over 60,000 people. With support from Ministry officials and the WHO, this UK biotech is making serious progress with their transgenic organism solution for Infectious diseases. UPDATE: (Article originally published 3/06/16). Just announced (14/07/16): The results from the trial […]

July 14, 2016 - 4 minutesmins - By Dani Bancroft

pharnext marie tooth disease IPO pharnext

News and Trends 14 Jul 2016

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s. Based in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. New partners to join this biotech in the €31M IPO include Galapagos […]

July 14, 2016 - 2 minutesmins - By Dani Bancroft

servier sorrento pd 1 biotech chemo car t cancer

News and Trends 13 Jul 2016

French Pharma licenses California PD-1 Cancer Antibody for €710M

San Diego’s Sorrento Therapeutics has bagged a quarter-billion euro deal with Servier. The French Pharma giant will develop Sorrento’s PD-1 targeting platform – a key checkpoint inhibitor in Immuno-Oncology. Sorrento’s proprietary G-MAB library platform was used to identify and generate STI-A1110, an antibody which targets PD-1, one of the key targets in the rapidly developing immuno-oncology therapy […]

July 13, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 13 Jul 2016

Europe’s most valuable Biotech just launched 2 new Trials

Within a week, Actelion has announced both Phase II and III trial studies for insomnia and hypertension in children. Even for Europe’s most valuable biotech, this is an impressive period. Actelion is to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia. The day before this, it also announced a […]

July 13, 2016 - 3 minutesmins - By Dani Bancroft

ono pharmaceutical biotech celyad cancer nk cell therapy

News and Trends 12 Jul 2016

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

Belgian Celyad granted an exclusive license to Osaka based ONO Pharmaceutical for the development and commercialisation of Celyad’s unique allogeneic cell therapy in Japan, Korea and Taiwan. This license agreement opens new markets to Celyad and its NKR-2 T-cell cancer immunotherapy. In addition to a deal worth up to €282M, Celyad will also receive double digit royalties based on […]

July 12, 2016 - 3 minutesmins - By Dani Bancroft

HIV diagnostic helen lee epo biotech inventor europe samba

News and Trends 12 Jul 2016

How did Helen Lee overcome barriers to HIV Diagnostics in the ‘Real World’?

How can diagnostics be improved in resource limited settings? And how can the practical limitations of transporting heat-sensitive assay material through hot climates be overcome? The University of Cambridge’s Dr Helen Lee won this year’s ‘Popular Choice’ Award, at the European Patent Office (EPO) awards. The winner of this prize category is selected from 15 other […]

July 12, 2016 - 6 minutesmins - By Dani Bancroft

News and Trends 11 Jul 2016

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs. The positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV. The Norwegian’s proprietary […]

July 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 11 Jul 2016

After Genentech, Roche could acquire another American Billion-dollar Biotech

Roche is rumored to make a move on the California biotech BioMarin. Despite a slightly weakened pipeline, Roche appears undeterred and previous offers were predicted to be around $15Bn. As big as some of the other industry veterans, BioMarin was founded in the 90’s boom in Biotech in San Rafaele, California. The deal itself is entirely based on […]

July 11, 2016 - 2 minutesmins - By Dani Bancroft

zika sanofi niaid army us vaccine biotech

News and Trends 7 Jul 2016

Sanofi and the US Army team up for a Zika Vaccine, but why isn’t everyone else?

Together with the US Walter Reed Army Institute of Research (WRAIR), the French infectious disease specialist, Sanofi Pasteur, hopes to speed up their promising new Zika virus vaccine. With the concerns over the borderline epidemic of the Zika virus, with its mysterious origins and not fully understood pathophysiology, the Biotech and pharmaceutical industries have united globally […]

July 7, 2016 - 4 minutesmins - By Dani Bancroft

multiple sclerosis zinbryta daclizumab biogen abbvie

News and Trends 6 Jul 2016

Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

Biogen and AbbVie have been granted EU marketing authorization for Zinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo. Biogen is trying to emphasise the need for choice of treatments for MS, as the […]

July 6, 2016 - 3 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Dani Bancroft

About

Articles by Dani Bancroft

Infographic: What are the key challenges in Personalized Medicine?

Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

UPDATE: Brazilian city to be first in World to deploy GM Mosquitos against Dengue Fever

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

French Pharma licenses California PD-1 Cancer Antibody for €710M

Europe’s most valuable Biotech just launched 2 new Trials

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

How did Helen Lee overcome barriers to HIV Diagnostics in the ‘Real World’?

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

After Genentech, Roche could acquire another American Billion-dollar Biotech

Sanofi and the US Army team up for a Zika Vaccine, but why isn’t everyone else?

Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

Subscribe to our newsletter to get the latest biotech news!